Epix Wins FDA Approval of Vasovist

12/22/08Follow @xconomy

Epix Pharmaceuticals, a Lexington, MA-based biotech company, said today it has received FDA clearance to market gadofosveset trisodium (Vasovist) as a new contrast agent to help doctors interpret magnetic resonance scans of narrowing arteries. Epix originally asked for FDA approval in December 2003. Shares of the company (NASDAQ: EPIX) more than doubled on the news, to 83 cents at 3:41 pm Eastern.

By posting a comment, you agree to our terms and conditions.